IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NCT05118334 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Non-small-cell Lung Cancer)

Interventions

DRUG: Sintilimab
DRUG: IBI310

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.